The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.
From 1991-2002, we treated 58 patients with multiple sclerosis (MS) using the humanised monoclonal antibody, Campath-1H, which causes prolonged T lymphocyte depletion. Clinical and surrogate markers of inflammation were suppressed. In both the relapsing-remitting (RR) and secondary progressive (SP)...
| Auteurs principaux: | , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Langue: | English |
| Publié: |
2006
|